A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice

Vaccine

Volumn 33, Issue 43, 2015, Pages 5779-5785

  Wang, Xiaoli ^a   Ku, Zhiqiang ^a   Dai, Wenlong ^a   Chen, Tan ^a   Ye, Xiaohua ^a   Zhang, Chao ^a   Zhang, Yingyi ^b   Liu, Qingwei ^a   Jin, Xia ^a   Huang, Zhong ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Combination vaccine; Enterovirus 71; Neutralizing antibody; Norovirus; Virus like particle

Indexed keywords

BACULOVIRUS VECTOR; ENTEROVIRUS 71 VIRUS LIKE PARTICLE VACCINE; MUCIN; NEUTRALIZING ANTIBODY; NOROVIRUS GENOGROUP II.4 VIRUS LIKE PARTICLE VACCINE; PROTEIN VP1; STOMACH MUCIN; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACULOVIRIDAE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG FORMULATION; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; CELL LINE; ENTEROVIRUS A; GENE VECTOR; GENETICS; IMMUNOLOGY; INSECT; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; BACULOVIRIDAE; CELL LINE; ENTEROVIRUS A, HUMAN; FEMALE; GENETIC VECTORS; INSECTS; MICE, INBRED BALB C; NEUTRALIZATION TESTS; NOROVIRUS; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84944089024     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.043     Document Type: Article

References (45)

1. Dennehy P.H. Viral gastroenteritis in children. Pediatr Infect Dis J 2011, 30(January (1)):63-64.
2. Patel M.M., Widdowson M.A., Glass R.I., Akazawa K., Vinje J., Parashar U.D. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008, 14(August (8)):1224-1231.
3. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002, 26(March (1)):91-107.
4. Wong S.S., Yip C.C., Lau S.K., Yuen K.Y. Human enterovirus 71 and hand, foot and mouth disease. Epidemiol Infect 2010, 138(August (8)):1071-1089.
5. Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010, 10(November (11)):778-790.
6. Lee T.C., Guo H.R., Su H.J., Yang Y.C., Chang H.L., Chen K.T. Diseases caused by enterovirus 71 infection. Pediatr Infect Dis J 2009, 28(October (10)):904-910.
7. Zheng D.P., Ando T., Fankhauser R.L., Beard R.S., Glass R.I., Monroe S.S. Norovirus classification and proposed strain nomenclature. Virology 2006, 346(March (2)):312-323.
8. Kroneman A., Vega E., Vennema H., Vinje J., White P.A., Hansman G., et al. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 2013, 158(October (10)):2059-2068.
9. Vega E., Barclay L., Gregoricus N., Shirley S.H., Lee D., Vinje J. Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013. J Clin Microbiol 2014, 52(January (1)):147-155.
10. Bok K., Abente E.J., Realpe-Quintero M., Mitra T., Sosnovtsev S.V., Kapikian A.Z., et al. Evolutionary dynamics of GII.4 noroviruses over a 34-year period. J Virol 2009, 83(November (22)):11890-11901.
11. Debbink K., Lindesmith L.C., Baric R.S. The state of norovirus vaccines. Clin Infect Dis 2014, 58(June (12)):1746-1752.
12. Atmar R.L., Estes M.K. Norovirus vaccine development: next steps. Expert Rev Vaccines 2012, 11(September (9)):1023-1025.
13. Richardson C., Bargatze R.F., Goodwin R., Mendelman P.M. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Expert Rev Vaccines 2013, 12(February (2)):155-167.
14. Fang H., Tan M., Xia M., Wang L., Jiang X. Norovirus P particle efficiently elicits innate, humoral and cellular immunity. PLOS ONE 2013, 8(4):e63269.
15. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S., Estes M.K. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003, 108(September (3)):241-247.
16. Liu F., Liu Q., Cai Y., Leng Q., Huang Z. Construction and characterization of an infectious clone of coxsackievirus A16. Virol J 2011, 8:534.
17. Xu J., Qian Y., Wang S., Serrano J.M., Li W., Huang Z., et al. EV71: an emerging infectious disease vaccine target in the Far East?. Vaccine 2010, 28(April (20)):3516-3521.
18. Lee M.S., Chang L.Y. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010, 9(February (2)):149-156.
19. Liang Z., Mao Q., Gao F., Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front Med 2012, (December).
20. Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T., et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008, 26(March (15)):1855-1862.
21. Ku Z., Ye X., Huang X., Cai Y., Liu Q., Li Y., et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLOS ONE 2013, 8(2):e57601.
22. Li H.Y., Han J.F., Qin C.F., Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 2013, 31(July (32)):3281-3287.
23. Ku Z., Liu Q., Ye X., Cai Y., Wang X., Shi J., et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 2014, 32(July (34)):4296-4303.
24. Lin Y.L., Yu C.I., Hu Y.C., Tsai T.J., Kuo Y.C., Chi W.K., et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 2012, 30(February (7)):1305-1312.
25. Lin Y.L., Hu Y.C., Liang C.C., Lin S.Y., Liang Y.C., Yuan H.P., et al. Enterovirus-71 virus-like particles induce the activation and maturation of human monocyte-derived dendritic cells through TLR4 signaling. PLOS ONE 2014, 9(10):e111496.
26. Liu Q., Ku Z., Cai Y., Sun B., Leng Q., Huang Z. Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins. J Virol Methods 2011, 173(April (1)):115-120.
27. Liu Q., Yan K., Feng Y., Huang X., Ku Z., Cai Y., et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 2012, 30(October (47)):6642-6648.
28. Reed L.J., Muench H. A simple method of estimating 50 percent endpoints. Am J Hyg 1938, 27:493-499.
29. Huang Z., Chen Q., Hjelm B., Arntzen C., Mason H. A DNA replicon system for rapid high-level production of virus-like particles in plants. Biotechnol Bioeng 2009, 103(July (4)):706-714.
30. Lindesmith L.C., Debbink K., Swanstrom J., Vinje J., Costantini V., Baric R.S., et al. Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol 2012, 86(January (2)):873-883.
31. Lindesmith L.C., Beltramello M., Donaldson E.F., Corti D., Swanstrom J., Debbink K., et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 2012, 8(5):e1002705.
32. Koho T., Huhti L., Blazevic V., Nurminen K., Butcher S.J., Laurinmaki P., et al. Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus. J Virol Methods 2012, 179(January (1)):1-7.
33. Lindesmith L., Moe C., Marionneau S., Ruvoen N., Jiang X., Lindblad L., et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003, 9(May (5)):548-553.
34. Reeck A., Kavanagh O., Estes M.K., Opekun A.R., Gilger M.A., Graham D.Y., et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010, 202(October (8)):1212-1218.
35. Atmar R.L., Bernstein D.I., Harro C.D., Al-Ibrahim M.S., Chen W.H., Ferreira J., et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011, 365(December (23)):2178-2187.
36. Rydell G.E., Kindberg E., Larson G., Svensson L. Susceptibility to winter vomiting disease: a sweet matter. Rev Med Virol 2011, 21(November (6)):370-382.
37. Tan M., Jiang X. Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends Microbiol 2011, 19(August (8)):382-388.
38. Tian P., Jiang X., Zhong W., Jensen H.M., Brandl M., Bates A.H., et al. Binding of recombinant norovirus like particle to histo-blood group antigen on cells in the lumen of pig duodenum. Res Vet Sci 2007, 83(December (3)):410-418.
39. Tian P., Yang D., Jiang X., Zhong W., Cannon J.L., Burkhardt W., et al. Specificity and kinetics of norovirus binding to magnetic bead-conjugated histo-blood group antigens. J Appl Microbiol 2010, 109(November (5)):1753-1762.
40. Bernstein D.I., Atmar R.L., Lyon G.M., Treanor J.J., Chen W.H., Jiang X., et al. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis 2015, 211(March (6)):870-878.
41. Cai Y., Ku Z., Liu Q., Leng Q., Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 2014, 32(May (21)):2406-2412.
42. Chokephaibulkit K., Perng G.C. Challenges for the formulation of a universal vaccine against dengue. Exp Biol Med (Maywood) 2013, 238(May (5)):566-578.
43. Coller B.A., Clements D.E. Dengue vaccines: progress and challenges. Curr Opin Immunol 2011, 23(June (3)):391-398.
44. Ye X., Ku Z., Liu Q., Wang X., Shi J., Zhang Y., et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 2014, 88(January (1)):72-81.
45. Jones M.K., Watanabe M., Zhu S., Graves C.L., Keyes L.R., Grau K.R., et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science 2014, 346(November (6210)):755-759.